Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Looks to Build Reputation in New York Market by Partnering with AMDeC

NEW YORK, March 9 (GenomeWeb News) - In an effort to raise its East Coast profile, NuGen will begin providing its Ovation RNA amplification systems to AMDeC Foundation, a consortium of more than 30 New York healthcare organizations, research institutions, and medical schools, the company said this week.


NuGen, which said it hoped its relationship with AMDeC would build the firm's reputation in the New York market, has also agreed to sponsor AMDeC initiatives in the future, and provide members with on-site training programs for its amplification kits.


"Our collaboration will give us greater visibility at many New YorkState medical research institutions and further solidify our reputation as a significant emerging company in the functional genomics market place," said Elizabeth Hutt, vice president of commercial operations at NuGen.


Maria Mitchell, the president of AMDeC, said that NuGen's Ovation kits would be useful in biomedical research conducted by members that include MemorialSloanKetteringCancerCenter and the Weill Medical College of Cornell University.


Financial details of the agreement were not discussed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.